MCA Stability Tool

Find stability recommendations for tablets and capsules.

Product Search

Stability Notes

Protect from light. Store in airtight container.

Provenance

This compatibility recommendation is derived from Zinnat 250mg tablets (Sandoz Ltd).

Stability Notes

Protect from light and moisture. Store in airtight containers.

Provenance

This compatibility recommendation is derived from generic cetirizine 10mg tablets.

Stability Notes

Protect from light and moisture. Store in airtight containers.

Provenance

This compatibility recommendation is derived from generic cetirizine 10mg tablets.

Stability Notes

No specific storage requirements.

Provenance

This compatibility recommendation is derived from Zithromax 250mg capsules (Pfizer Ltd).

Stability Notes

Slightly hygroscopic. Protect from light. Max 7 days in MCA.

Provenance

This compatibility recommendation is derived from Besavar XL 10mg tablets (Zentiva Pharma UK Ltd), Xatral XL 10mg tablets (Sanofi) and Vasran XL 10mg tablets (Ranbaxy (UK) Ltd).

Stability Notes

Protect from light and moisture.

Provenance

This compatibility recommendation is derived from Zocor 10mg tablets (Organon Pharma (UK) Ltd).

Stability Notes

Protect from light and moisture.

Provenance

This compatibility recommendation is derived from Zocor 20mg tablets (Organon Pharma (UK) Ltd).

Stability Notes

Protect from light and moisture.

Provenance

This compatibility recommendation is derived from Zocor 20mg tablets (Organon Pharma (UK) Ltd).

Stability Notes

Protect from light and moisture.

Provenance

This compatibility recommendation is derived from Zocor 20mg tablets (Organon Pharma (UK) Ltd).

Stability Notes

Protect from light and moisture.

Provenance

This compatibility recommendation is derived from Zocor 40mg tablets (Organon Pharma (UK) Ltd).

Print this list

Medicines suitable for use in MCAs, although use is likely to be off-label.  Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed).  Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices.  Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.
There are concerns about stability and/or there is a lack of stability data available. These medicines can theoretically be used in MCAs, although use is likely to be off-label.  Mitigation measures may need to be considered.  Keep medicines in MCAs for the shortest time necessary.  Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed). Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices. Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.
Medicines under this category are not suitable for use in MCAs.
These medicines have not been reviewed by SPS.